Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1)
IL17Frs763780 single nucleotide polymorphism is associated with asthma after bronchiolitis in infancy
Julkaisun tekijät: Holster A, Terasjarvi J, Barkoff AM, Lauhkonen E, Tormanen S, Helminen M, Korppi M, He QS, Nuolivirta K
Kustantaja: WILEY
Julkaisuvuosi: 2021
Journal: Acta Paediatrica
Tietokannassa oleva lehden nimi: ACTA PAEDIATRICA
Lehden akronyymi: ACTA PAEDIATR
Volyymi: 110
Julkaisunumero: 1
Sivujen määrä: 6
ISSN: 0803-5253
DOI: http://dx.doi.org/10.1111/apa.15390
Verkko-osoite: https://onlinelibrary.wiley.com/doi/full/10.1111/apa.15390
Tiivistelmä
Aim Interleukin-17F (IL-17F) is involved with asthma. The aim of this study was to evaluate the association ofIL17Fpolymorphisms with childhood asthma after bronchiolitis in infancy. Methods We invited 166 children who were hospitalised for bronchiolitis at younger than 6 months of age to follow-up visits at 5-7 years and 11-13 years of ages. Asthma and allergy diagnoses, asthma-presumptive symptoms and use of inhaled corticosteroids (ICSs) were registered. Blood samples were available forIL17Frs763780 (T/C), rs11465553 (C/T) and rs7741835 (C/T) determinations in 165 cases. Results The presence ofIL17Frs11465553 and rs7741835 variations showed no significant associations with any asthma or allergy outcome at either 5-7 years or 11-13 years of ages. Instead, children with the variantIL17Frs763780 genotype had used more often ICSs between the follow-up visits from 5-7 to 11-13 years (adjusted OR 3.58) than those with the wild genotype. Children with the variantIL17Frs763780 genotype reported more often doctor-diagnosed atopic dermatitis (adjusted OR 2.71) at 11-13 years of age than those with the wild genotype. Conclusion This prospective long-term follow-up study provided preliminary evidence on the association of theIL17Frs763780 polymorphism with asthma at school age after bronchiolitis in infancy.
Aim Interleukin-17F (IL-17F) is involved with asthma. The aim of this study was to evaluate the association ofIL17Fpolymorphisms with childhood asthma after bronchiolitis in infancy. Methods We invited 166 children who were hospitalised for bronchiolitis at younger than 6 months of age to follow-up visits at 5-7 years and 11-13 years of ages. Asthma and allergy diagnoses, asthma-presumptive symptoms and use of inhaled corticosteroids (ICSs) were registered. Blood samples were available forIL17Frs763780 (T/C), rs11465553 (C/T) and rs7741835 (C/T) determinations in 165 cases. Results The presence ofIL17Frs11465553 and rs7741835 variations showed no significant associations with any asthma or allergy outcome at either 5-7 years or 11-13 years of ages. Instead, children with the variantIL17Frs763780 genotype had used more often ICSs between the follow-up visits from 5-7 to 11-13 years (adjusted OR 3.58) than those with the wild genotype. Children with the variantIL17Frs763780 genotype reported more often doctor-diagnosed atopic dermatitis (adjusted OR 2.71) at 11-13 years of age than those with the wild genotype. Conclusion This prospective long-term follow-up study provided preliminary evidence on the association of theIL17Frs763780 polymorphism with asthma at school age after bronchiolitis in infancy.